Appendix Table C28. Clinical renal outcomes (outcomes part C), ACEI plus ARB versus ACEI plus aldosterone antagonist trial

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **End-Stage Renal Disease, n/N (%)** | | **Doubling of Serum Creatinine, n/N (%)** | | **Halving of GFR, n/N (%)** | | **Progression from Micro- to Macroalbuminuria, n/N (%)** | | **Composite Renal Outcome, n/N (%)** | |
| **ACEI+ ARB** | **ACEI+ AA** | **ACEI+ ARB** | **ACEI+ AA** | **ACEI+ ARB** | **ACEI+ AA** | **ACEI+ ARB** | **ACEI+ AA** | **ACEI+ ARB** | **ACEI+ AA** |
| Mehdi, 200945 |  |  | 13/26 (50.0) | 13/27 (48.0) |  |  |  |  |  |  |

GFR = glomerular filtration rate; ACEI = angiotension converting enzyme; ARB = angiotensin receptor blocker: AA = aldosterone antagonist